(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2011 (24.03.2011)

PCT

(10) International Publication Number
WO 2011/034604 A2

(51) **International Patent Classification**:
A61K 9/00 (2006.01)

(21) **International Application Number**:
PCT/US2010/002545

(22) **International Filing Date**:
16 September 2010 (16.09.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/277,045 17 September 2009 (17.09.2009) US

(71) **Applicants** *(for all designated States except US)*: **BAXTER HEALTHCARE, S.A.** [CH/CH]; Thurgauerstrasse 130, CH-8152 Glattpark (Opfikon) (CH). **BAXTER INTERNATIONAL, INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **TESCHNER, Wolfgang** [DE/AT]; Gestettengasse 19/14, A-1030 Wien (AT). **SVATOS, Sonja** [AT/AT]; Kapellengasse 42, A-2413 Berg (AT). **BRUCKSCHWAIGER, Leopold** [AT/AT]; Herminengasse 5/14, A-1020 Wien (AT). **WEBER, Alfred** [AT/AT]; Skraupstrasse 24/42/8, A-1210 Wien (AT). **SCHWARZ, Hans-Peter** [AT/AT]; Weimarer Strasse 76, A-1180 Wien (AT). **LEI, Laura** [US/US]; 11452 Clarkson Road, Los Angeles, CA 90064 (US).

(74) **Agents**: **SEIDMAN, Stephanie, L.** et al.; K&L GATES LLP, 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/034604 A2

(54) **Title**: STABLE CO-FORMULATION OF HYALURONIDASE AND IMMUNOGLOBULIN, AND METHODS OF USE THEREOF

(57) **Abstract**: Provided herein are stable co-formulations of immunoglobulin and hyaluronidase that are stable to storage in liquid form at room temperature for at least 6 months and at standard refrigerator temperatures for 1-2 years. Such co-formulations can be used in methods of treating IG-treatable diseases or conditions by subcutaneous administration.